Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
Recruiting
Phase 4
Interventional Study
End Stage Renal Disease on Dialysis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 30 (estimated)
- Sponsor
- Yale University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis.
This is a randomized, placebo controlled, acute crossover study of empagliflozin in an anticipated 30 chronic PD patients, with an 8 week "pre post" open label extension in all 30 patients where they will receive empaglifloz…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria
1. Patients actively undergoing PD with a reliably functioning PD catheter
2. Stable peritoneal dialysis prescription
3. PD vintage \> 3 months
4. Age \>18 years of age
Exclusion Criteria:
1. History of type 1 diabetes, diabetic ketoacidosis, "brittle" diabetes or frequent hypo…
Contacts